Reply to the enhancing the accuracy of seroprevalence studies: Reassessing pertussis infection rates in Eastern China during the COVID-19 pandemic

Xiang Suna Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China

Wen Wangb Department of Rheumatology and Immunology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, ChinaCorrespondence[email protected]
View further author information

References

Daungsupawong H, Wiwanitkit V. Enhancing the accuracy of seroprevalence studies: reassessing pertussis infection rates in Eastern China during the COVID-19 pandemic. Hum Vaccin Immunother. 2024 Mar 24;20(1):2340765. doi:10.1080/21645515.2024.2340765.
PubMed Web of Science ®Google Scholar
Sun X, Zhang T, Sun J, Zhou J, Chen Q, Jia C, Xu Y, Wu Y, Wang Z, Wang W. The seroepidemiology of immunoglobulin G antibodies against pertussis toxin and filamentous hemagglutinin in the East of China during the COVID-19 pandemic. Hum Vaccin Immunother. 2024 Dec 31;20(1):2331438. doi:10.1080/21645515.2024.2331438.
PubMed Web of Science ®Google Scholar
De Greeff SC, Teunis P, de Melker HE, Mooi FR, Notermans DW, Elvers B, Schellekens JFP. Two-component cluster analysis of a large serodiagnostic database for specificity of increases of IgG antibodies against pertussis toxin in paired serum samples and of absolute values in single serum samples. Clin Vaccine Immunol. 2012 Sep;19(9):1452–2. doi:10.1128/CVI.00229-12.
PubMedGoogle Scholar